General Information of Drug (ID: DMDYVN8)

Drug Name
MEDI-528 Drug Info
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMDYVN8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Interleukin-9 (IL9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BNZ-1 DM8JQZC Cutaneous T-cell lymphoma 2B01 Phase 2 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-9 (IL9) TT0JTFD IL9_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT00507130) A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma
2 Clinical pipeline report, company report or official report of AstraZeneca (2009).
3 Clinical pipeline report, company report or official report of Bioniz Therapeutics.